Glucose biosensor system coupled with an anti-inflammatory module and methods for using the same
View Patent ↗Disclosed are apparatuses for detecting glucose levels in a subject. The apparatuses include a glucose sensor coupled with an anti-inflammatory module. The apparatus is configured to monitor blood glucose by detecting the fluorescence generated by the sensor and simultaneously reduce the tissue inflammation reaction. Also disclosed are biosensor systems including the apparatuses and methods of using the biosensor systems.
1. An implantable glucose sensor, the sensor comprising:
a population of alginate microspheres loaded with one or more anti-inflammatory agents, wherein the population is a mixture of uncoated and polyelectrolyte-coated alginate microspheres, and wherein the polyelectrolyte-coated alginate microspheres comprise an outer polyelectrolyte layer that is chemically or covalently cross-linked; and
a population of dissolved core alginate microspheres incorporating one or more fluorophore-labeled glucose binding agents and one or more fluorophore-labeled glucose analogues.
2. The implantable glucose sensor of claim 1 , wherein the dissolved core alginate microspheres have an average diameter of about 10 μm to about 20 μm.
3. The implantable glucose sensor of claim 1 , wherein the population of alginate microspheres loaded with the one or more anti-inflammatory agents comprise from about 25% to about 90% polyelectrolyte coated microspheres.
4. The implantable glucose sensor of claim 3 , wherein the population of alginate microspheres loaded with the one or more anti-inflammatory agents comprise about 75% polyelectrolyte coated microspheres and about 25% uncoated microspheres.
5. The implantable glucose sensor of claim 1 , wherein the fluorophore on the one or more fluorophore-labeled glucose binding agents and the fluorophore on the one or more fluorophore-labeled glucose analogues form a FRET pair.
6. The implantable glucose sensor of claim 1 , wherein the glucose binding agent is selected from the group consisting of: apo-glucose oxidase, Concanavalin A, and glucose binding protein.
7. The implantable glucose sensor of claim 1 , wherein the one or more glucose analogues is selected from the group consisting of dextran amino, dextran, and β-cyclodextrin.
8. The implantable glucose sensor of claim 1 , wherein the one or more anti-inflammatory agents are selected from the group consisting of: dexamethasone, hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, betamethasone, triamcinolone, diclofenac, ibuprofen, naproxen, and celecoxib.
9. The implantable glucose sensor of claim 1 , wherein the polyelectrolyte comprise at least one bilayer of a polycation and a polyanion.
10. The implantable glucose sensor of claim 9 , wherein the polycation is selected from the group consisting of: poly(allylamine hydrochloride) (PAH) and poly(diallyldimethylammonium chloride) (PDDA).
11. The implantable glucose sensor of claim 9 , wherein the polyanion is selected from the group consisting of: poly(styrene sulfonate) (PSS) and poly(acrylic acid) (PAA).
12. The implantable glucose sensor of claim 9 , wherein the at least one bilayer comprises a polyelectrolyte pair selected from the group consisting of: PAH/PSS, PDDA/PSS, PAH/PAA and cross-linked PAA/PAH.
13. The implantable glucose sensor of claim 1 , wherein the alginate microspheres loaded with the one or more anti-inflammatory agents comprise from about 25% to about 90% by weight of the implantable glucose sensor and the dissolved core alginate microspheres comprise from about 50% to about 80% by weight of the implantable glucose sensor.
14. The implantable glucose sensor of claim 1 , wherein the dissolved core alginate microspheres further comprise a reference fluorophore in a polyelectrolyte coating.
15. The implantable glucose sensor of claim 14 , wherein the reference fluorophore is AF-750 tagged to a PAH polyelectrolyte.
16. A method for monitoring the blood glucose of a subject, the method comprising:
detecting a fluorescence emission from an implanted glucose sensor, wherein the implanted glucose sensor comprises a population of alginate microspheres loaded with one or more anti-inflammatory agents, wherein the population is a mixture of uncoated and polyelectrolyte-coated alginate microspheres, and wherein the polyelectrolyte-coated alginate microspheres comprise an outer polyelectrolyte layer that is chemically or covalently cross-linked; and a population of dissolved core alginate microspheres incorporating one or more fluorophore-labeled glucose binding agents and one or more fluorophore-labeled glucose analogues;
wherein the change in intensity of the fluorescence emission compared to a reference fluorescence is correlated to the blood glucose level of the subject.
17. The method of claim 16 , further comprising detecting the fluorescence emission of the reference fluorophore.
18. The method of claim 16 , wherein a ratio of the fluorescence emission from the one or more fluorophore-labeled glucose analogue compared to the fluorescence emission from the one or more fluorophore-labeled glucose binding agents is correlated to the blood glucose level of the subject.
19. The method of claim 17 , wherein a ratio of the fluorescence emission from the one or more fluorophore-labeled glucose binding agents compared to the fluorescence emission of the reference fluorophore is correlated to the blood glucose level of the subject.
20. A kit for monitoring the blood glucose of a subject, the kit comprising:
a population of alginate microspheres loaded with one or more anti-inflammatory agents, wherein the population is a mixture of uncoated and polyelectrolyte-coated alginate microspheres, wherein the polyelectrolyte-coated alginate microspheres comprise an outer polyelectrolyte layer that is chemically or covalently cross-linked;
a population of dissolved core alginate microspheres incorporating one or more fluorophore-labeled glucose binding agents and one or more fluorophore-labeled glucose analogues; and
optical instrumentation for detecting fluorescence emission from the one or more fluorophore-labeled glucose binding agents.